ADH4-a potential prognostic marker for hepatocellular carcinoma with possible immune-related implications

• Published in: BMC cancer 2024-08, Vol.24 (1), p.927-14, Article 927
• Main Authors: Li, Ling, Huang, Yong-Ta, Wang, Li-Ting, Wang, Xiao-Ling, Chen, Zhen-Yu, Jiang, Shao-Lan, Zeng, Qiu-Ling, Huang, Hui-Pin, Li, Xiao-Long
• Format: Article
• Language: English
• Subjects: ADH4 protein; Alcohol; Alcohol Dehydrogenase - genetics; Alcohol Dehydrogenase - metabolism; Alcohol dehydrogenase 4 (ADH4); Analysis; Bioinformatics; Biological markers; Biomarkers; Biomarkers, Tumor - genetics; Biomarkers, Tumor - metabolism; Cancer immunotherapy; Carcinoma, Hepatocellular - genetics; Carcinoma, Hepatocellular - immunology; Carcinoma, Hepatocellular - mortality; Carcinoma, Hepatocellular - pathology; Care and treatment; CD19 antigen; CD4 antigen; Cell cycle; Correlation analysis; Datasets; Female; Gene expression; Gene Expression Regulation, Neoplastic; Hepatocellular carcinoma; Hepatoma; Humans; Immune response; Immune-related; Immunohistochemistry; Immunomodulation; Immunotherapy; Kaplan-Meier Estimate; Liver; Liver cancer; Liver Neoplasms - genetics; Liver Neoplasms - immunology; Liver Neoplasms - mortality; Liver Neoplasms - pathology; Male; Medical prognosis; Metabolism; Patient outcomes; Prognosis; Radiofrequency ablation; Software; Statistical analysis; Statistical significance; Survival analysis; Transplantation; Variables
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-024-12675-y

This study aims to explore ADH4 expression in hepatocellular carcinoma (HCC), its prognostic impact, and its immune correlation to provide novel insights into HCC prognostication and treatment. HCC prognostic marker genes were rigorously selected using GEO database, Lasso regression, GEPIA, Kaplan-Meier and pROC analyses. The expression of interested markers (ADH4, DNASE1L3, RDH16, LCAT, HGFAC) in HCC and adjacent tissues was assessed by Immunohistochemistry (IHC). We observed that ADH4 exhibited low expression levels in liver cancer tissues and high expression levels in normal liver tissues. However, the remaining four genes did not manifest any statistically significant differences between hepatocellular carcinoma (HCC) tissue and adjacent non-cancerous tissue. Consequently, ADH4 became the primary focus of our research. ADH4 expression was validated by signed-rank tests and unpaired Wilcoxon rank sum tests across pan-cancer and HCC datasets. Clinical significance and associations with clinicopathological variables were determined using Kaplan-Meier, logistic regression and Cox analyses on TCGA data. The ADH4-related immune responses were explored by Spearman correlation analysis using TIMER2 data. CD68, CD4, and CD19 protein levels were confirmed by IHC in HCC and non-cancerous tissues. ADH4 showed significant downregulation in various cancers, particularly in HCC. Moreover, low ADH4 expression was associated with clinicopathological variables and served as an independent prognostic marker for HCC patients. Additionally, ADH4 affects a variety of biochemical functions and may influence cancer development, prognosis, and treatment by binding to immune cells. Furthermore, at the immune level, the low expression pattern of ADH4 is TME-specific, indicating that ADH4 has the potential to be used as a target for cancer immunotherapy. This study highlights the diagnostic, prognostic and immunomodulatory roles of ADH4 in HCC. ADH4 could serve as a valuable biomarker for HCC diagnosis and prognosis, as well as a potential target for immunotherapeutic interventions.